key: cord-0715539-2rzl60kk
authors: Drewett, George P.; Chan, R. Kimberley; Jones, Nicholas; Wimaleswaran, Hari; Howard, Mark E.; McDonald, Christine F.; Kwong, Jason; Smibert, Olivia; Holmes, Natasha E.; Trubiano, Jason A.
title: Risk factors for readmission following inpatient management of COVID‐19 in a low‐prevalence setting
date: 2021-05-27
journal: Intern Med J
DOI: 10.1111/imj.15218
sha: 3b019324c5251765d9aebcd5ed78cecc9353454d
doc_id: 715539
cord_uid: 2rzl60kk

nan

There are minimal data on post-COVID-19 readmissions in relatively low-prevalence countries such as Australia. Data prior to COVID-19 demonstrate that hospitalised patients have up to a 20% chance of a 30-day unplanned readmission, representing a significant human, financial and resource burden. 1 We performed a single-centre, observational cohort study of inpatients admitted to Austin Health from March to October 2020, investigating demographic, clinical, laboratory and treatment parameters associated with readmission to hospital within 6 months following initial inpatient management of COVID-19. Patients with a single index admission were compared to those readmitted, then grouped according to reason for readmission (i.e. respiratory or COVID-19-specific symptoms, complications of COVID-19, or unrelated presentation). Chi-squared and rank sum tests were performed for univariate analysis using Stata MP16.1 (StataCorp, College Station, TX, USA). Data from the index admission are summarised in Table 1 . Of 169 patients admitted with COVID-19 between March and October 2020 who survived to discharge, 24 (14.2%) were readmitted to hospital within 6 months (median, 36 days; interquartile range, 15-67 days). Ten (5.9%) patients re-presented with respiratory or COVID-19-specific symptoms, five (3.0%) patients re-presented with COVID-19 complications, and nine (5.3%) patients re-presented with unrelated problems (Supporting Information Table S1 ).

In whole cohort analysis, increased length of stay during index admission was significantly associated with readmission (5 days vs 7 days, P = 0.04). A nonsignificant increase in readmission was noted in patients with pre-existing chronic respiratory disease, patients requiring supplemental oxygen, and patients admitted to the intensive care unit (ICU). In sub-group analysis of only those patients who re-presented with respiratory or COVID-19-specific symptoms or complications of COVID-19 (n = 15), ICU admission (P = 0.04), supplemental oxygen (P = 0.03) and highflow nasal oxygen (HFNO) (P = 0.01) were significantly associated with readmission. Of those who represented within 30 days of index admission (n = 12), readmission was increased in patients with preexisting chronic respiratory disease (21.7% vs 41.7%, P = 0.12), and a significant association was found with HFNO (P = 0.004).

To our knowledge, this is the first study investigating readmission trends following hospitalisation with COVID-19 in a low-prevalence country. Our data compare with a large US registry study that reported a 60day re-presentation rate of 9%, a COVID-19-related representation rate of 45%, and included respiratory comorbidity as a risk for re-presentation. 3 We found a positive association between length of stay and readmission, in contrast to other studies where premature discharge was thought to contribute to 'bounceback' admissions. 3, 4 Although limited by small numbers and single-centre follow up, we found an association between parameters indicating a more severe illness course (ICU, HFNO, length of stay) and readmission, although no association between National Institutes of Health (NIH)-calculated severity of index illness at presentation 2 and readmission. International experience investigating early readmission after COVID-19 hospitalisation shows mixed results; 4,5 however, an increased likelihood of readmission in patients requiring HFNO in index admission has been associated with poor prognosis in other studies. 6 As length of stay, ICU admission, supplemental oxygen requirement and HFNO were associated with readmission for COVID-19 or associated complications, this group of patients should be a focus for targeted postacute care. 2 ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCI, Charlson Comorbidity Index (age adjusted); CRP, C-reactive protein; CXR, chest X-ray; ICU, intensive care unit; IQR, interquartile range, LDH, lactate dehydrogenase; NIH, National Institutes of Health.

Utility of models to predict 28-day or 30-day unplanned hospital readmissions: an updated systematic review

COVID-19) Treatment Guidelines. Maryland: National Institutes of Health

Characteristics of hospitalized COVID-19 patients discharged and experiencing samehospital readmission -United States

Return hospital admissions among 1419 COVID-19 patients discharged from five U.S. Emergency Departments

Characterization of patients who return to hospital following discharge from hospitalization for COVID-19

High-flow nasal oxygen in coronavirus disease 2019 patients with acute hypoxemic respiratory failure: a multicenter, retrospective cohort study